© Reuters. FILE PHOTO: Moderna logo is seen displayed in this illustration taken, May 3, 2022. REUTERS/Dado Ruvic/Illustration
(Reuters) – Moderna (NASDAQ:) Inc on Wednesday agreed to buy Japan-based OriCiro Genomics for $85 million to boost the U.S. drugmaker’s mRNA manufacturing capabilities.
OriCiro’s technologies will support Moderna’s portfolio of therapeutics and vaccines, the companies said.
Be the first to comment